Nilutamide
- TRADE NAMES: Anandron (Sanofi-Aventis); Nilandron (Concordia)
- INDICATIONS: Metastatic prostate cancer, androgen-independent prostate cancer
- CLASS: Androgen antagonist, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Aminophylline, Aspirin, Chlordiazepoxide, Diazepam, Lidocaine, Phenytoin, Propranolol, Warfarin
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 08/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
